Document is current
Any future updates will be listed below
-
Authors
Nierenberg, Jovia L.
Adamson, Aaron W.
Hu, Donglei https://orcid.org/0000-0002-0351-001X
Huntsman, Scott
Patrick, Carmina https://orcid.org/0000-0002-8248-818X
Li, Min
Steele, Linda
Tao, Shu https://orcid.org/0000-0001-5177-6771
Ding, Yuan Chun
Tong, Barry
Shieh, Yiwey https://orcid.org/0000-0002-0159-7748
Fejerman, Laura https://orcid.org/0000-0003-3179-1151
Gruber, Stephen B. https://orcid.org/0000-0001-8656-7822
Haiman, Christopher A.
John, Esther M.
Kushi, Lawrence H. https://orcid.org/0000-0001-9136-1175
Torres-Mejía, Gabriela
Ricker, Charité
Weitzel, Jeffrey N. https://orcid.org/0000-0001-6714-092X
Ziv, Elad https://orcid.org/0000-0002-2324-2884
Neuhausen, Susan L. https://orcid.org/0000-0001-5053-0390
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA184585, K24CA169004, R01CA120120)
- License Information
-
More Information
Article History
Received: 1 September 2023
Accepted: 28 May 2025
First Online: 21 August 2025
Competing interests
: J.L.N. is an employee and shareholder at BridgeBio Pharma, this work was done prior to her work at BridgeBio Pharma. J.N.W. is a consultant to Natera, MyOme and Cancer IQ, holds equity in Natera and is a co-founder of Novi Health. All other authors declare no competing interests.
